Dexcom

DexCom Class Action Lawsuit Filed Over Securities Violations Allegations

Dexcom Launches Dexcom Academy, Personalized Learning Platform for Healthcare Professionals.

Dexcom Launches Dexcom Academy, a Personalized Learning Platform for Healthcare Professionals.

Levi & Korsinsky Files Securities Fraud Lawsuit Against DexCom, Inc.

U.S. Manufacturing Shrinks for Ninth Straight Month Amid Decline in New Orders and Employment

Catalyst<ul> <li>Strong cash reserves relative to market value indicate solid fundamental strength for DXCM.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are clearly dominant with three bearish versus no bullish technical signals.</li> <li>Fund flows are negative across all order sizes, suggesting investor pessimism toward DXCM.</li> <li>Analyst ratings show differences with only one Buy and one Neutral rating, indicating uncertain market expectations.</li></ul>

Key Factors

A class action lawsuit alleges DexCom violated the Securities Exchange Act of 1934 by misleading investors about product changes and FDA authorization between July 2024 and September 2025. DexCom launched Dexcom Academy, a personalized learning platform for healthcare professionals, now available in Belgium, Germany, Saudi Arabia, the Netherlands, and Spain. Morgan Stanley upgraded DexCom to Overweight with a price target of $75, citing its potential in a growing market and progress on operational issues.

DXCM News